Inhibition_NN
of_IN
HIV-1_NN
replication_NN
by_IN
combination_NN
of_IN
a_DT
novel_JJ
inhibitor_NN
of_IN
TNF-alpha_NN
with_IN
AZT_NN
._.

The_DT
small_JJ
molecule_NN
S9a_NN
was_VBD
derived_VBN
from_IN
an_DT
established_JJ
tumor_NN
necrosis_NN
factor-alpha_NN
-LRB-_-LRB-
TNF-alpha_NN
-RRB-_-RRB-
inhibitor_NN
-LRB-_-LRB-
Canventol_NN
-RRB-_-RRB-
by_IN
replacement_NN
of_IN
the_DT
isopropylidine_NN
group_NN
with_IN
a_DT
phenyl_NN
ring_NN
._.

S9a_NN
at_IN
10_CD
to_TO
100_CD
nM_NN
inhibited_VBD
HIV_NN
production_NN
as_IN
potently_RB
as_RB
3_CD
'_``
-_JJ
azido-3_NN
'_''
-_:
deoxythymidine_NN
-LRB-_-LRB-
AZT_NN
-RRB-_-RRB-
,_,
an_DT
inhibitor_NN
of_IN
viral_JJ
reverse_JJ
transcriptase_NN
._.

Furthermore_RB
,_,
S9a_NN
and_CC
AZT_NN
in_IN
combination_NN
,_,
at_IN
noncytoxic_JJ
concentrations_NNS
strongly_RB
inhibited_VBD
HIV-1_NN
replication_NN
that_WDT
was_VBD
more_RBR
than_IN
additive_JJ
and_CC
substantially_RB
prolonged_JJ
the_DT
appearance_NN
of_IN
virus_NN
both_CC
in_IN
acutely_RB
infected_JJ
CD4_NN
+_CC
lymphocytes_NNS
-LRB-_-LRB-
SupT_NN
-RRB-_-RRB-
in_IN
culture_NN
and_CC
in_IN
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
-LRB-_-LRB-
PBMCs_NNS
-RRB-_-RRB-
infected_VBN
with_IN
a_DT
primary_JJ
HIV-1_NN
isolate_NN
._.

S9a_NN
inhibited_VBD
TNF-alpha_NN
promoter-driven_JJ
reporter_NN
gene_NN
activity_NN
._.

It_PRP
was_VBD
proposed_VBN
that_IN
the_DT
mechanism_NN
of_IN
antiviral_JJ
action_NN
of_IN
S9a_NN
was_VBD
on_IN
the_DT
host_NN
cell_NN
,_,
by_IN
blocking_VBG
TNF-alpha_NN
transcription_NN
via_IN
a_DT
Tat-induced_JJ
tar-independent_JJ
loop_NN
,_,
which_WDT
decreases_VBZ
downstream_JJ
NF-kappaB_NN
activation_NN
of_IN
HIV-1_NN
long_JJ
terminal_JJ
repeat_NN
-LRB-_-LRB-
LTR_NN
-RRB-_-RRB-
._.

S9a_NN
was_VBD
superior_JJ
to_TO
the_DT
first_JJ
generation_NN
compound_NN
Canventol_NN
,_,
which_WDT
was_VBD
superior_JJ
to_TO
the_DT
natural_JJ
compound_NN
sarcophytol_NN
A_NN
,_,
demonstrating_VBG
that_IN
further_JJ
structure-based_JJ
enhancement_NN
of_IN
potency_NN
of_IN
these_DT
compounds_NNS
is_VBZ
feasible_JJ
._.

This_DT
study_NN
suggests_VBZ
a_DT
therapeutic_JJ
approach_NN
against_IN
AIDS_NN
by_IN
application_NN
of_IN
two_CD
drugs_NNS
,_,
one_CD
against_IN
a_DT
cellular_JJ
and_CC
the_DT
other_JJ
a_DT
viral_JJ
target_NN
,_,
which_WDT
may_MD
provide_VB
an_DT
approach_NN
to_TO
the_DT
problem_NN
of_IN
frequent_JJ
emergence_NN
of_IN
resistant_JJ
variants_NNS
to_TO
combinations_NNS
of_IN
drugs_NNS
that_WDT
target_VBP
only_JJ
HIV_NN
genes_NNS
._.

